Biocon filings after Q1FY27: a more detailed disclosure, generics turns profitable, and biosimilars keep growing
Biocon Limited (NSE: BIOCON, BSE: 532523) reported consolidated revenue of ₹4,336 crore for Q1 FY27 on 5 August 2026, 10 % higher than the same quarter a year earlier, according to BSE results filings the same day. Consolidated EBITDA was ₹901.7 crore and the EBITDA margin widened to 20.8 %, the filings show. A separate investor presentation filed on 6 August 2026 described a 355 % year‑on‑year surge in reported net profit.
Biocon Limited (NSE: BIOCON, BSE: 532523) reported consolidated revenue of ₹4,336 crore for Q1 FY27 on 5 August 2026, 10 % higher than the same quarter a year earlier, according to BSE results filings the same day. Consolidated EBITDA was ₹901.7 crore and the EBITDA margin widened to 20.8 %, the filings show. A separate investor presentation filed on 6 August 2026 described a 355 % year‑on‑year surge in reported net profit.
The quarter also brought a first in the track‑record our platform’s filings pipeline covers: Biocon published an investor presentation with segment detail and held a conference call for Q1, both captured by BSE filings on 6 August and 11 August 2026 respectively. The documents offer a snapshot of where the financials are turning and what management has flagged for the rest of FY27.
Generics profitability turnaround is “in progress”
In the 11 August 2026 conference call, management described the generics segment as having turned profitable, saying “operating leverage has started to play” and that “margin expansion will remain a priority.” The call transcript, filed on BSE, frames the generics improvement as a turnaround that is being driven by product mix, cost synergies and disciplined R&D. The same transcript notes that further scale‑up is expected as new launches – liraglutide was named – ramp.
Biosimilars grow 16 %; services contract sharply
The 5 August 2026 results filing that provides segment colour shows biosimilars up 16 % year‑on‑year, while generics growth helped the biopharma segment expand 17 %. The services segment (Syngene) contracted 16 % during the quarter, pulling overall revenue growth to the 10 % level and leaving EBITDA margin broadly flat versus the year‑ago quarter, despite the sequential improvement within the other businesses.
The balance‑sheet moves in June–September
Several other BSE filings in the same window signal structural and strategic steps:
- On 29 June 2026 Biocon completed the acquisition of the remaining 11,536,956 equity shares of Biocon Biologics Limited from 127 selling shareholders via a preferential share swap, making Biocon Biologics a wholly‑owned subsidiary (BSE filing dated 29 June 2026).
- On 3 August 2026 Biocon announced the commercial launch of Yesafili™, an FDA‑approved interchangeable biosimilar to Eylea® 2 mg, in the United States (filing 3 August 2026).
- On 25 August 2026 the company disclosed that Japan’s Ministry of Health, Labour and Welfare had granted marketing approval for its pegfilgrastim biosimilar; Sandoz K.K. will handle distribution (filing 25 August 2026).
- On 8 September 2026 a BSE filing revealed a 10‑year supply contract for Pertuzumab, a HER2‑positive breast cancer therapy, under Brazil’s Productive Development Partnership (PDP) programme. The consortium received 100 % allocation, giving exclusive access to Brazil’s public market – approximately 70 % of demand. Biocon will earn milestone payments and a revenue share.
Management: H2 acceleration and a Syngene recovery are the stated targets
On the 11 August 2026 conference call, management stated that the second half of FY27 should see acceleration, with a recovery in the Services segment described as part of the outlook. The call transcript mentions that new launches in generics, including liraglutide, are expected to contribute to the ramp in coming quarters.
Alpha Inflection is research infrastructure, not investment advice. We are not SEBI‑registered investment advisers. Everything above is compiled from public corporate filings, with sources cited. Do your own research.
The filing evidence
| Date | What the filing said | Detail | Source |
|---|---|---|---|
| 5 Aug 2026 | Q1FY27 consolidated revenue was ₹43,360 million, +10.0% YoY but -4.0% QoQ, while EBITDA margin rose to 20.8% and shareholder PAT increased to ₹1,411 million; the operating recovery is improving, but PAT remains supported by other income and EPS dilution. | filing | |
| 5 Aug 2026 | Q1FY27 consolidated revenue was ₹4336 million, up 10.0% YoY, while PAT rose to ₹141.1 million and EBITDA margin expanded to 20.8%; biosimilars and generics grew but services sharply contracted and earnings quality remains mixed. | filing | |
| 6 Aug 2026 | Biocon's Q1 FY27 earnings reflect steady revenue growth of 10% YoY and a dramatic 355% surge in reported net profit, driven by biosimilars and generics, though near-term challenges persist in the services segment. | filing | |
| 11 Aug 2026 | Biocon Q1 FY27 biosimilars up 16%, generics turns profitable, Syngene decline drives mixed start; management targets H2 acceleration and Syngene recovery. | filing | |
| 10 Jun 2026 | Biocon Limited acquires equity stake in Ampin C&I Power Twelve Private Limited to enhance renewable energy consumption | Biocon Limited has acquired an equity stake in Ampin C&I Power Twelve Private Limited (AMPIN), a company engaged in the generation and supply of solar power. | filing |
| 22 Jun 2026 | Biocon Limited informs shareholders about tax deduction at source (TDS) on the recommended final dividend for FY2025-26, pending shareholder approval. | Biocon Limited communicated to its shareholders regarding the TDS provisions applicable to the final dividend of Re. 0.50 per share recommended by the Board for FY2025-26, subject to approval at the AGM on August 6, 2026. The communication details TDS rates for resident and non-resident shareholders, required documentation to claim lower withholding rates, and the deadline of July 20, 2026 for submitting forms. | filing |
| 29 Jun 2026 | Biocon completes acquisition of Biocon Biologics equity from 127 shareholders via preferential share swap, making BBL a wholly-owned subsidiary. | Biocon Limited acquired 11,536,956 equity shares of its material subsidiary Biocon Biologics Limited (BBL) from 127 selling shareholders, and as consideration, issued and allotted 8,786,362 new equity shares of Biocon on a preferential basis to those sellers at Rs. 376.41 per share, resulting in BBL becoming a wholly-owned subsidiary effective June 29, 2026. | filing |
| 29 Jun 2026 | Biocon completes acquisition of remaining 11.5 million shares of Biocon Biologics from 127 shareholders via a preferential share swap, making Biocon Biologics a wholly-owned subsidiary. | Biocon Limited acquired 11,536,956 equity shares of its material subsidiary Biocon Biologics Limited (BBL) from 127 selling shareholders. As consideration, Biocon issued and allotted 8,786,362 new equity shares on a preferential basis at Rs. 376.41 per share, using shareholder approval obtained on June 7, 2026. Post-transaction, BBL became a wholly-owned subsidiary of Biocon. | filing |
| 9 Jul 2026 | Biocon announces publication of pivotal clinical data for Yesafili™, a biosimilar to Eylea®, supporting its effectiveness in treating diabetic macular edema. | Biocon announced the publication of two clinical studies from the Phase III INSIGHT program for Yesafili™ (aflibercept-jbvf) in peer-reviewed journals, demonstrating similar safety, efficacy, and immunogenicity outcomes between patients who continued on the biosimilar and those who switched from reference aflibercept, as well as comparable efficacy across diverse patient subgroups. | filing |
| 3 Aug 2026 | Biocon launches Yesafili™, a biosimilar to Eylea®, in the U.S. for treating serious eye conditions. | Biocon announced the commercial launch of Yesafili™ (aflibercept-jbvf), an FDA-approved interchangeable biosimilar to Regeneron's Eylea® 2 mg, in the United States on August 3, 2026. | filing |
| 5 Aug 2026 | Q1FY27 operating revenue was ₹4,336 crore, up 10% YoY, and EBITDA was ₹901.7 crore, up 7%, as 17% Biopharma growth offset a 16% Services decline, but margin remained broadly flat YoY and sequentially weaker. | filing | |
| 25 Aug 2026 | Biocon receives Japanese MHLW marketing approval for its pegfilgrastim biosimilar, strengthening its biosimilar portfolio in Japan. | Biocon Biologics, a wholly-owned subsidiary of Biocon, obtained marketing approval from Japan's Ministry of Health, Labour and Welfare for its pegfilgrastim biosimilar (biosimilar to Neulasta). Sandoz K.K. will exclusively promote, sell, and distribute the product in Japan. | filing |
| 8 Sept 2026 | Biocon secures a 10-year supply contract for Pertuzumab under Brazil's PDP program, gaining exclusive access to the country's public healthcare market. | Biocon signed a partnership agreement with Bahiafarma and Bionovis for the supply of Pertuzumab, a HER2-positive breast cancer therapy, under Brazil's Productive Development Partnership (PDP) program. The consortium received 100% allocation under the 10-year PDP, giving exclusive access to Brazil's public market (~70% of demand). Biocon will receive milestone payments and revenue share. | filing |
Quick answers
- What did Biocon disclose?
- Biocon Limited (NSE: BIOCON, BSE: 532523) reported consolidated revenue of ₹4,336 crore for Q1 FY27 on 5 August 2026, 10 % higher than the same quarter a year earlier, according to BSE results filings the same day. Consolidated EBITDA was ₹901.7 crore and the EBITDA margin widened to 20.8 %, the filings show.
- What are the key numbers?
- The 5 August 2026 results filing that provides segment colour shows biosimilars up 16 % year‑on‑year, while generics growth helped the biopharma segment expand 17 %.
Research and educational content only. Not investment advice. Drafted from regulatory filings and published automatically — see our editorial policy.